Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025

Data from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiyi WangYZYu ZhangXLXiangdong Li

Discussion

Loading...

Member takes

Overview

Analysis reveals Trem2's influence on immunotherapy response in NASH-driven HCC, suggesting new treatment strategies.

Key Points

  • Trem2 acts as a central regulator in the immunosuppressive niche of NASH-driven HCC, enhancing anti-PD-1 therapy efficacy.
  • Clinical evidence shows a correlation between elevated Trem2 and the presence of immunosuppressive T cells in NASH-related HCC.
  • Myeloid-specific knockout of Trem2 led to increased proinflammatory macrophages, negatively affecting NET degradation.
  • Combination therapy targeting Trem2 and NETosis may overcome resistance to immunotherapy in metabolic liver cancer.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219a1https://doi.org/10.1158/2326-6066.c.8065132
View Full Paper
Ask AI
Bookmark
Share